Beam Therapeutics Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Cambridge, MA
BEAM chart
What traders are saying about $BEAM
Latest postsBeam Therapeutics Inc. news
- BEAM Stock Climbs On First Look At One-Time GSDIa Gene Fix; H.C. Wainwright Sees Further 200% Upside
stocktwits.com ·
- H.C. Wainwright says Beam Therapeutics data strengthens confidence
TipRanks ·
- Beam Therapeutics Reports Early BEAM-301 Gains in GSD1a Fasting Tolerance
marketbeat.com ·
- Wedbush Adjusts Beam Therapeutics PT to $28 From $65, Maintains Outperform Rating
marketscreener.com ·
- Beam Therapeutics reports initial data from BEAM-301 trial
TipRanks ·
- Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress
Yahoo Finance ·
- Beam Therapeutics, Inc. Estimates – BMV:BEAM
TradingView ·
- BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM)
ChartMill ·
- Beam Therapeutics (BEAM) Institutional Ownership 2026
MarketBeat ·
- DOSTI Hosts Career and Networking Event for Indian-Origin Life Sciences Professionals
INDIA New England News ·
- Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
fool.com ·
- Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress
Yahoo Finance ·
Beam Therapeutics Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M |
| Net income | -$80.0M | -$376.7M | -$132.5M | -$289.1M |
| Diluted EPS | $-0.81 | $-4.58 | $-1.72 | $-4.13 |
| Total assets (year end) | $1.48B | $1.10B | $1.46B | $1.34B |
| Cash and equivalents (year end) | $294.9M | $282.0M | $435.9M | $232.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Beam Therapeutics Inc.
- Ticker
- BEAM (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Cambridge, MA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1745999
- Former names
- Beam Therapeutics Inc.
Frequently asked questions
What exchange is Beam Therapeutics Inc. listed on?
Beam Therapeutics Inc. trades on the Nasdaq under the ticker symbol BEAM.
What industry is Beam Therapeutics Inc. in?
Beam Therapeutics Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Beam Therapeutics Inc. headquartered?
Beam Therapeutics Inc.'s business address on file with the SEC is in Cambridge, MA.
When does Beam Therapeutics Inc.'s fiscal year end?
Beam Therapeutics Inc.'s fiscal year ends on December 31.
How much revenue did Beam Therapeutics Inc. report?
Beam Therapeutics Inc. reported $139.7M in revenue for calendar year 2025, according to its SEC filings.